Drug Profile
Research programme: hepatitis C therapy - Crucell
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Stanford University
- Developer Crucell
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in Netherlands (Parenteral)
- 22 Feb 2011 Crucell has been acquired by Johnson & Johnson
- 06 May 2009 Preclinical trials in Hepatitis C in Netherlands (Parenteral)